

Safety "Clinical Trial" of the Cardiac Liability of COVID19 Polytherapy

Grant Award Details

Safety "Clinical Trial" of the Cardiac Liability of COVID19 Polytherapy

Grant Type: Progression Award - Discovery Stage Research Projects

Grant Number: DISC2P-11946

Project Objective: The objective is to validate a stem cell-based microphysiological system (MPS) for predicting cardiac toxicity, including modeling drug-drug interactions in polytherapy for the treatment of SARS-CoV-2 in patients with diverse backgrounds

Investigator:

Name:	Kevin Healy
Institution:	University of California, Berkeley
Type:	PI

Disease Focus: COVID-19, Infectious Disease

Human Stem Cell Use: iPS Cell

Award Value: \$224,500

Status: Pre-Active

Grant Application Details

Application Title: Safety "Clinical Trial" of the Cardiac Liability of COVID19 Polytherapy

Public Abstract:

Statement of Benefit to California:

Source URL: <https://www.cirm.ca.gov/our-progress/awards/safety-%E2%80%99Clinical-trial%E2%80%99D-cardiac-liability-covid19-polytherapy>